Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.

Abstract excerpt

Glioblastoma (GBM) is the most common malignant brain tumour in adults. Current prognosis with standard treatment is poor. Immunotherapy is a new paradigm in tumour management. Specifically, recent advances in the field of immune checkpoint molecules have led to dramatic results in many cancers. Inhibition of one particular, programmed cell death-1 (PD-1) has recently been shown to be highly effective in melanoma...

Topics

Join the communities discussing this publication.

• Antineoplastic Agents, Immunological
• Brain Neoplasms
• Glioblastoma
• Immunotherapy
• Phenotype